<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123145</url>
  </required_header>
  <id_info>
    <org_study_id>CARENFER IRC</org_study_id>
    <nct_id>NCT04123145</nct_id>
  </id_info>
  <brief_title>Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)</brief_title>
  <official_title>Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIFORFRANCE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIFORFRANCE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite its known prevalence, a recent study conducted with Prof. Cacoub (unpublished) on the&#xD;
      national health insurance database showed that iron deficiency was a poorly diagnosed and&#xD;
      poorly treated comorbidity. In patients with Chronic Kidney Disease but Non-Dialysis, the&#xD;
      determination of Ferritinemia and Transferrin Saturation Factoris performed in only 30% and&#xD;
      10% of cases whereas they should be performed routinely in inflammatory situations and in&#xD;
      case of anemia (HAS 2011, KDIGO 2012). The objective of this study is to obtain updated data&#xD;
      on the prevalence of iron deficiency in France in patients with CKD-ND, applying the&#xD;
      international recommendations and those of the French Health High Authority (determination of&#xD;
      ferritinemia and Transferrin Saturation Factor).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 15, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete blood iron status</measure>
    <time_frame>One day</time_frame>
    <description>ferritin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete blood iron status</measure>
    <time_frame>One day</time_frame>
    <description>Transferrin Saturation Factor</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>CDK-ND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Iron status testing</intervention_name>
    <description>Iron status testing</description>
    <arm_group_label>CDK-ND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female, over 18 years of age;&#xD;
&#xD;
          -  Patient present at the hospital on the day of the study (traditional hospitalization,&#xD;
             week hospital, day hospital, or in consultation with CKD-ND);&#xD;
&#xD;
          -  Diagnosis of CKD-ND (glomerular filtration rate (GFR) &gt; 15 mL/min/1.73 mÂ²)&#xD;
&#xD;
          -  Patient with signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected patient: major under guardianship, tutorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  Patient with dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

